Site menu

Search by ticker code:
Generic filters


Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Why the Resmed (ASX: RMD) share price is charging higher today

The Resmed CDI (ASX: RMD) share price bounced 6.5% higher today following the release of its Q3 results on Friday.

The RMD share price closed flat on Friday, in a muted reaction to a beat to consensus sales and profit numbers. However, the share price caught up on Monday with the news being digested and investors reacting positively to it.

Resmed’s Result

The sleep apnoea devices and masks company reported sales increased +29% quarter over quarter to US$1.11 billion, or +31% on a constant currency basis. Resmed cited a production ramp-up and robust deliveries of sleep apnoea devices following supply chain disruptions and chip shortages experienced previously.

Gross margins contracted by 150 basis points to 55.3% due to an unfavourable product mix and higher component costs, partially offset by an increase in average selling prices.

SG&A expenses increased by 28% with higher employee and travel-related costs as a result of the increased device sales.

The net result was income from operations improved by +28%, and EPS (earning per share) came in at US$1.58 for the quarter, vs FY23 consensus of US$6 per share (referencing the US stock price for Resmedi, which is US$225 due to the dual listing). This implies a run rate of EPS that might be tracking ahead of consensus expectations which is generally a key positive driver of share price performance.

RMD also noted that cloud-connected device SaaS revenues continued to grow strongly. The acquisition of MEDIFOX DAN and continued organic growth in its SaaS portfolio contributed to this +35% segment growth.

Resmed earnings growth

RMD continues to benefit from the recall that competitor Phillips is experiencing after its sleep devices malfunctioned. These issues typically take many years to resolve when looking at similar cases historically, so RMD should continue to grow market share.

Covid induced supply chain issues and chip/component shortages caused “allocations” (customers receiving fewer devices than ordered). Historically gross margins have come in at 58-60%. This result saw gross margins of 55.3%. Analysts see these factors normalising over time to support earnings growth.

Resmed’s outlook

Resmed continues to experience growth across all major geographies (US, Canada, Latin America, Europe, Asia).

Management commentary implies that it has sold 156 million devices to patients and it is well on its way to achieve 250 million people by 2025, which would suggest continued high market penetration in a large addressable market that is still in its early stage of uptake.

We think pockets of ASX healthcare stocks remain good value given shares have lagged broader indices since covid. RMD (~30x P/E) and CSL Limited (ASX: CSL) (~32x P/E) look more attractive from a valuation perspective relative to Cochlear Ltd (ASX: COH) (~49x P/E) which has rallied recently to a more elevated valuation. You can read my recent updates on CSL shares here.

Resmed’s dividend

Resmed declared a quarterly dividend of US$0.44 per share distribution (unfranked due to overseas earnings). For its Aussie shares this equates to 4.44 cents per quarter, or 17 cents when annualised, implying a 0.5% yield. RMD remains a growth stock rather than a dividend income play.

3 ASX dividend stocks in 2024 (I recommend to everyone)

I’ve just released a special free report to Rask readers covering the 3 top ASX dividend stocks I recommend to EVERY INVESTOR in 2024. You can get my full report free by clicking here.

It’s a totally free report covering 3 ASX shares with big dividends, growth and attractive valuations for 2024 and beyond. It takes only 30 seconds to get the report.

When you get my report, you’ll instantly become part of my exclusive market insights report, “This Week on the Desk”. It includes some of my latest high-conviction ASX stock ideas, research and unique insights.

Simply click here to get my free report and receive my 3 top stocks ideas in 2024.

If you’d like access to our ALL our ideas in 2024, schedule a call with Luke today.

Want to read our updated top 3 dividend shares from the ASX for 2024?

Seneca General Advice Disclaimer

This investment report was written by Luke Laretive, founder of Seneca Financial Solutions. Seneca holds an Australian Financial Service License (AFSL No. 492686) and is regulated by the Australian Securities and Investments Committee (ASIC). The information contained in this email is general in nature and does not take into account your personal situation. You should consider whether the information is appropriate to your needs, and where appropriate, seek professional advice from a financial adviser. Luke Laretive, Seneca Financial Solutions, its Directors and its associated entities may have or had interests in the companies mentioned. Although every effort has been made to verify the accuracy of the information contained in this article, all liability (except for any liability which by law cannot be excluded), for any error, inaccuracy in, or omission from the information contained in this email or any loss or damage suffered by any person directly or indirectly through relying on this information. Read Seneca’s Terms, Financial Services Guide, Privacy Policy.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Luke Laretive or his clients may have a financial interest, for or against, any of the companies mentioned in this article.

Powered by

Skip to content